Übersicht

Eignung

Details zum Design

Arme & Interventionen

Ergebnismessungen

Studienzentren

Quelle: NCT05498792

Rekrutierung

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Interventionsstudie

Frühe Phase 1

Fox Chase Cancer Center

Phase I, open label, dose-escalation, and safety study designed to assess the safety and biologic activity of the investigational agent CBL0137 in combination with standard of care drugs, ipilimumab and nivolumab in sequential cohorts of adult patients with locally advanced and metastatic melanoma who are candidates for immune checkpoint blockade and have tumors accessible for serial biopsies.

Detaillierte Beschreibung anzeigen

Behandlungskategorie

Andere Medikamente, Checkpoint-Inhibitoren

Erforderliche Mutationen

Keine

Studie gestartet

2022-11-30

Zuletzt vom Sponsor aktualisiert

2025-04-04

Voraussichtlicher Abschluss

2026-03-04

Eignung

Einschlusskriterien

1. Patients must have:

1. Pathologically proven stage III melanoma with one or more macroscopic lymph node metastases (measurable according to RECIST v. 1.1) amenable to biopsy and/or surgery OR:

2. Patients considered to have stage III or stage IV disease amenable to serial biopsies as determined by the treating physician. Note: patients with in-transit metastasis may be eligible after surgical consultation if not surgical candidates.

3. Patients must have disease amenable to and must be willing to undergo protocol-directed repeat biopsies and blood draws.

2. Age > 18 years

3. ECOG performance status 0 or 1

4. Patients must have normal organ and marrow function

Ausschlusskriterien

1. Patients may not be receiving any other investigational agents

2. Patients with a known active autoimmune disease

3. Prior treatment with CTLA-4 or PD1/PD-L1 pathway targeted systemic treatment

4. Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic corticosteroids

5. Patients with ongoing diarrhea (> 4 bowel movements/day) unresolved despite medical and best supportive care in the two weeks preceding therapy

Glauben Sie, dass diese klinische Studie fälschlicherweise angezeigt wird?

Design-Details

ZuteilungNon-Randomized

InterventionsmodellSingle Group Assignment

MaskierungNone (Open Label)

Anzahl der Teilnehmer12

Arme & Interventionen

Arme

Interventionen

Typ: Experimental

Beschreibung: Dose level 1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.

Interventionen:

CBL0137
Ipilimumab
Nivolumab

Ergebnismessungen

Primäre Ergebnismessungen

Initial assessment of safety and tolerability of the combination of CBL0137 with Nivolumab and Ipilimumab.28 days

The primary endpoint will be safety/tolerability of the combination of CBL0137 with ipilimumab and nivolumab. Patients will be treated as part of assigned dose level in planned 3+ 3 design with 3 possible dose levels and assessed for Dose limiting toxicities ( DLTs)

Sekundäre Ergebnismessungen

Keine

Interessiert an einer Teilnahme?

Erfahren Sie mehr über diese Studie und ob Sie für eine Teilnahme in Frage kommen.

Studie vormerken

Studie per E-Mail teilen

Studie herunterladen

Glauben Sie, dass diese klinische Studie fälschlicherweise angezeigt wird?

Studie melden

Studie herunterladen

Studienzentren

Diese Studie hat 1 Studienzentrum

Fox Chase Cancer Center
Philadelphia, Pennsylvania, US

Rekrutierend

Philadelphia, Pennsylvania, 19111 US

Fox Chase Cancer Center

Loading Maps...